- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 558
View more information in the IUPHAR Pharmacology Education Project: salbutamol
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Highly selective β2-adrenoceptor agonist used in the treatment of COPD and asthma.
In April 2015, the FDA expanded approval to include treatment or prevention of bronchospasm in patients with reversible obstructive airway disease and for the treatment of exercise-induced bronchospasm (EIB).
|Mechanism Of Action and Pharmacodynamic Effects|
|Agonism of β2-adrenergic receptors in the lungs results in smooth muscle relaxation of bronchial smooth muscle. This is believed to be through the mechanism of increased cAMP production via adenylate cyclase activation. Increased levels of cAMP increase activity levels of protein kinase A which inhibits phosphorylation of myosin and lowers intracellular calcium concentrations leading to smooth muscle relaxation and bronchodilation. Salbutamol also inhibits the release of bronchoconstricting agents from mast cells, enhances mucociliary clearance and inhibits microvascular leakage.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)